title: Iterative and prolonged remission in metastatic breast cancer using pegylated irinotecan: a case report.
abstract: BACKGROUND
  Pegylated irinotecan NKTR-102 is a topoisomerase I inhibitor-polymer conjugate. This new formulation of irinotecan has been evaluated in a phase II clinical trial and is showing remarkable activity. To the best of our knowledge, this is the first case report of an impressive iterative response to pegylated irinotecan NKTR-102 in metastatic breast cancer.
  
  
  METHODS
  We report the case of a 49-year-old Caucasian woman diagnosed with metastatic luminal A breast cancer with initial bone followed by liver and bone marrow metastases, treated with three lines of hormonal therapy, targeted therapy and six lines of chemotherapy. She showed no major response to conventional treatment, whereas, the tumor shrinkage under pegylated irinotecan NKTR-102 was impressive, durable and iterative.
  
  
  CONCLUSIONS
  Reintroduction of an active drug is a valid approach as illustrated by our case. The results of the current phase III trials of pegylated irinotecan NKTR-102 are eagerly awaited.
authors.affiliation: Department of Medical Oncology, National Institute of Oncology, Université Mohammed V de Rabat, Avenue Allal El Fassi, 10100, Rabat, Morocco. mounia.amzerin@gmail.com.
authors.forename: Mounia
authors.initials: M
authors.lastname: Amzerin
authors.affiliation: Department of Medical Oncology, Jules Bordet Institute, Université Libre de Bruxelles, Boulevard de Waterloo 125, B-1000, Brussels, Belgium. maha.mokrim@bordet.be.
authors.forename: Maha
authors.initials: M
authors.lastname: Mokrim
authors.affiliation: Department of Medical Oncology, National Institute of Oncology, Université Mohammed V de Rabat, Avenue Allal El Fassi, 10100, Rabat, Morocco. h_errihani@yahoo.fr.
authors.forename: Hassan
authors.initials: H
authors.lastname: Errihani
authors.affiliation: Department of Medical Oncology, Jules Bordet Institute, Université Libre de Bruxelles, Boulevard de Waterloo 125, B-1000, Brussels, Belgium. martine.piccart@bordet.be.
authors.forename: Martine J
authors.initials: MJ
authors.lastname: Piccart
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D012074:Remission Induction; D059004:Topoisomerase I Inhibitors / Q000627:therapeutic use
chemical_list: D059004:Topoisomerase I Inhibitors; D000077146:Irinotecan; D002166:Camptothecin